Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.
about
Stability engineering of the human antibody repertoireThe neonatal Fc receptor, FcRn, as a target for drug delivery and therapyEngineered Fc based antibody domains and fragments as novel scaffolds.Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infectionsEngineered Autonomous Human Variable DomainsEngineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRnInteractions of IgG1 CH2 and CH3 Domains with FcRn.Vaginal microbicides and their delivery platforms.Orally active-targeted drug delivery systems for proteins and peptides.Single-domain antibodies for biomedical applications.Chemically modified peptides and proteins - critical considerations for oral delivery.HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.Molecular dynamics simulation of the crystallizable fragment of IgG1-insights for the design of FcabsCorrelations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding.Biofunctional analysis of Vitellogenin and Vitellogenin receptor in citrus red mites, Panonychus citri by RNA interference.Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.Single-Domain Antibodies As Therapeutics against Human Viral Diseases.Stabilization of the third fibronectin type III domain of human tenascin-C through minimal mutation and rational design.
P2860
Q26859495-FA6198E3-FA79-46F0-A9A4-21E8E2830352Q28257521-5493DA54-B412-4539-9F73-961C5C195AC8Q34289289-DED2989A-178C-4D37-9240-65ECA7AE3EE0Q34550963-19B9BFB6-56E4-4D2B-A7DC-BF31E14589BEQ35019893-C75A22F6-612E-44E5-9148-CF3A22872DACQ36140177-36A4C3FF-0150-4CC2-8FF6-A416C6182625Q36214076-B3D595E6-E837-4852-865E-1EB94228634EQ37692950-14FE2966-D34E-45E6-B7B6-911B0A4BF65BQ38186138-A1D6B11A-F58A-41C4-97EF-8D2B522C2AB5Q38223053-5D8692A7-EE9E-4BF3-94A1-620434AD1175Q38628712-0F70E43C-D77E-4964-BFDF-2189E312C9DAQ38881431-5452A1FA-3E3C-44A4-8546-9A0E625DE527Q40152011-F361B672-8A8B-4303-9A89-B25BA00AE1A5Q41778455-54728152-33C2-4655-9849-1D2C1C8357A7Q42107564-CE51A669-16F9-4D20-8C3E-225E7C9EAAA1Q47358163-CA9F6B3F-AFC7-4FC1-A0FA-8407CCCEA1B2Q47369553-7C188F8C-C06D-4A1A-9108-52BEC2A15126Q47548498-5AE45058-AF0C-4ACB-8F8B-646A355E5E37Q47554821-6B13ABE6-656B-487E-8A8C-F9C1F48CE432Q53509578-B9052912-F66E-4F8C-83D8-31770EFF1542
P2860
Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Engineered soluble monomeric I ...... gn of biological therapeutics.
@en
Engineered soluble monomeric I ...... gn of biological therapeutics.
@nl
type
label
Engineered soluble monomeric I ...... gn of biological therapeutics.
@en
Engineered soluble monomeric I ...... gn of biological therapeutics.
@nl
prefLabel
Engineered soluble monomeric I ...... gn of biological therapeutics.
@en
Engineered soluble monomeric I ...... gn of biological therapeutics.
@nl
P2093
P2860
P356
P1476
Engineered soluble monomeric I ...... ign of biological therapeutics
@en
P2093
Dimiter S Dimitrov
Weizao Chen
Yanping Wang
P2860
P304
25154-25164
P356
10.1074/JBC.M113.484154
P407
P50
P577
2013-07-18T00:00:00Z